Insider Buying: Galectin Therapeutics Director Buys 1,000 Shares of Stock (GALT)
Galectin Therapeutics (NASDAQ:GALT) Director Kevin D. Freeman bought 1,000 shares of the company’s stock on the open market in a transaction dated Friday, August 15th. The stock was purchased at an average price of $4.70 per share, with a total value of $4,700.00. Following the completion of the transaction, the director now directly owns 3,917 shares of the company’s stock, valued at approximately $18,410. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Galectin Therapeutics (NASDAQ:GALT) opened at 4.58 on Wednesday. Galectin Therapeutics has a 1-year low of $4.28 and a 1-year high of $19.11. The stock’s 50-day moving average is $9.66 and its 200-day moving average is $12.64. The company’s market cap is $101.0 million.
Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.17) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.04. On average, analysts predict that Galectin Therapeutics will post $-1.03 earnings per share for the current fiscal year.
GALT has been the subject of a number of recent research reports. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.
Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.